Biopharma Leaders Unite To Stand With Science
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
Let's personalize your content